Revospirone (Bay Vq 7813) is an azapirone drug which was patented as a veterinary tranquilizer but was never marketed.[1] It acts as a selective 5-HT1A receptor partial agonist.[2] Similarly to other azapirones such as buspirone, revospirone produces 1-(2-pyrimidinyl)piperazine (1-PP) as an active metabolite.[2] As a result, it also acts as an α2-adrenergic receptor antagonist to an extent.[2]
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H21N5O3S |
| Molar mass | 387.46 g·mol−1 |
References
edit- ^ Macdonald F (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1744. ISBN 978-0-412-46630-4. Retrieved 13 May 2012.
- ^ a b c Löscher W, Witte U, Fredow G, Traber J, Glaser T (September 1990). "The behavioural responses to 8-OH-DPAT, ipsapirone and the novel 5-HT1A receptor agonist Bay Vq 7813 in the pig". Naunyn-Schmiedeberg's Archives of Pharmacology. 342 (3): 271–7. doi:10.1007/bf00169437. PMID 2149168. S2CID 24769939.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |